References: 1. STIOLTO RESPIMAT [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; 2016. 2. Jones PW, Forde Y. St George’s Respiratory Questionnaire Manual. London, UK: St George’s, University of London; 2009. 3. Singh D, Ferguson GT, Bolitschek J, et al. Tiotropium + olodaterol shows clinically meaningful improvements in quality of life. Respir Med. 2015;109(10):1312–1319. 4. Jones PW. Interpreting thresholds for a clinically significant change in health status in asthma and COPD. Eur Respir J. 2002;19:398–404. 5. Data on file. Boehringer Ingelheim Pharmaceuticals, Inc.
Treatment Goal 1: Lung Function (FEV1)
References: 1. STIOLTO RESPIMAT [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; 2016. 2. Buhl R, Maltais F, Abrahams R, et al. Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2–4). Eur Respir J. 2005;45(4): 869–871. 3. SPIRIVA RESPIMAT [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; 2016. 4. Data on file. Boehringer Ingelheim Pharmaceuticals, Inc. 5. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. http://goldcopd.org/gold-2017-global-strategy-diagnosis-management-prevention-copd/. Updated January 2017. Accessed February 22, 2017. 6. Chronic obstructive pulmonary disease – quick-relief drugs. National Institutes of Health Medline Plus Web site. https://www.nlm.nih.gov/medlineplus/ency/patientinstructions/000026.htm. Updated February 2, 2016. Accessed January 26, 2017. 7. Tantucci C, Modina D. Lung function decline in COPD. Int J COPD. 2012;7:95–99. 8. Vestbo J, Edwards LD, Scanlon PD, Yates JC. Changes in forced expiratory volume in 1 second over time in COPD. NEJM. 2011;365(13):1184–1192.
Treatment Goal 2: Health-Related Quality of Life1,2
Treatment Goal 3: Improved Delivery
Deliver the medicine deep into the patients’ lungs with STIOLTO RESPIMAT 1-3
STIOLTO is NOT a rescue medication and does NOT replace fast-acting inhalers to treat acute symptoms.
STIOLTO RESPIMAT is engineered specifically for patients who need inhaled therapy. It starts working in 5 minutes and lasts a full 24 hours1,4,5.
RESPIMAT can help your patients with:
- Lung deposition: The mist is composed of highly respirable, small particle-sized droplets1
- Inhalation effort: RESPIMAT inhaler delivers medicine independent of inspiratory effort and helps get medication deep into patients’ lungs
- Coordination: RESPIMAT inhaler may help facilitate actuation and inhalation
As with all inhaled drugs, the actual amount of drug delivered to the lung may depend on patient factors, such as the coordination between the actuation of the inhaler and inspiration through the delivery system. The duration of inspiration should be at least as long as the spray duration (1.5 seconds).
Consider once-daily STIOLTO to help your COPD patients reach key treatment goals.
References: 1. Brand P, Hederer B, Austen G, Dewberry H, Meyer T. Higher lung deposition with Respimat Soft Mist Inhaler than HFA MDI in COPD patients with poor technique. Int J COPD. 2008;3(4):763–770. 2. Newman SP, Brown J, Steed KP, Reader SJ, Kladders H. Lung deposition of fenoterol and flunisolide delivered using a novel device for inhaled medicines: comparison of RESPIMAT with conventional metered dose inhalers with and without spacer devices. Chest. 1998;113(4):957–963. 3. Pitcairn G, Reader S, Pavia D, Newman S. Deposition of corticosteroid aerosol in the human lung by Respimat Soft Mist Inhaler compared to deposition by metered dose inhaler or by Turbuhaler dry powder inhaler. J Aerosol Med. 2005;18(3):264–272. 4. Dalby RN, Eicher J, Zierenberg B. Development of Respimat Soft Mist Inhaler and its clinical utility in respiratory disorders. Med Devices (Auckl). 2011;4:145–155. 5. STIOLTO RESPIMAT [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; 2016.